HealthcareNasdaqsmall
Institutional-grade research for retail investors
SEC EDGAR: CIK 1711786RKTO stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

RKTO Stock Analysis & AI Quality Score

Data updated 2026-07-26

AI stock analysis and institutional research for Rocket One Inc. (RKTO), a Healthcare sector company. RKTO is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Rocket One Inc. reports net income of $-2.7M, free cash flow of $-3.1M. RKTO trades on the Nasdaq exchange and files with the SEC under CIK 1711786. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RKTO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Rocket One Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-2.7M

Free Cash Flow

Q1 2026

$-3.1M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-1.0% YoY
$-8.2MFY 2024
FY21 $-14.3MFY22 $-11.4MFY23 $-8.1MFY24 $-8.2M

Operating Income

-3.3% YoY
$-8.2MFY 2024
FY21 $-14.1MFY22 $-11.1MFY23 $-8.0MFY24 $-8.2M

EPS (Diluted)

+46.2% YoY
$-1.28FY 2024
FY21 $-16.02FY22 $-9.50FY23 $-2.38FY24 $-1.28

Total Assets

-19.0% YoY
$7.7MFY 2024
FY21 $11.0MFY22 $7.7MFY23 $9.5MFY24 $7.7M

Op. Cash Flow

+17.4% YoY
$-7.0MFY 2024
FY21 $-12.1MFY22 $-9.3MFY23 $-8.4MFY24 $-7.0M

AI Insight: RKTO Financial Trends

Hoth is a pre-revenue biotech burning $2–4M per quarter with equity eroded from $9M to $4M over two years.

Revenue remains zero across all periods; company is entirely pre-commercialization with no product sales.

Net income losses ranged $2–4M per quarter; Q3 2025 peaked at $4M loss, latest quarter Q1 2026 at $3M loss.

Equity declined 55% from $9M (Q2 2024) to $4M (Q1 2026), reflecting cumulative losses and cash burn.

Operating cash flow remains negative ($2–3M per quarter); no path to cash-generating operations visible.

Equity cushion now critically thin at $4M; continued $2–3M quarterly burn pressures runway and dilution risk.

AI Insight: RKTO Ratio Trends

Hoth Therapeutics remains deeply unprofitable with no visible path to positive returns; ROE deteriorated sharply to -199.5% in Q3 2025 before improving only modestly to -174.8% in Q4 2025.

ROE worsened from -90.3% in Q2 2025 to -199.5% in Q3 2025, a 109pp deterioration in a single quarter.

ROA collapsed to -93.8% in Q3 2024 and remained deeply negative at -87.0% in Q2 2025; no recovery visible.

ROIC tracked negative across all available observations: -66.0% (Q2 2024), -90.3% (Q2 2025); value destruction persistent.

ROE swing from -174.8% (Q4 2025) to missing data (Q1 2026) suggests either seasonal stabilization or reporting gap—verify next filing.

No leverage data (D/E) reported across any quarter; debt position and capital structure remain opaque.

Get alerted when RKTO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Rocket One Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of RKTO

Put RKTO on your watchlist

Track score changes the day Rocket One Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is RKTO a good stock to buy?

13F Pro's AI-powered analysis of Rocket One Inc. (RKTO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RKTO are available on the RKTO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. RKTO is classified as a small company.

Which hedge funds own RKTO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RKTO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Rocket One Inc.'s investment landscape.